Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: Data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study. Wiley.
शिकागो शैली (17वां संस्करण) प्रशस्ति पत्रNash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-term Extension Study. Wiley, 2018.
एमएलए (9वां संस्करण) प्रशस्ति पत्रNash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-term Extension Study. Wiley, 2018.